Description: Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat pain. Its products include intravenous CR845 that has completed Phase II clinical trials for the treatment of acute postoperative pain in adult patients; Oral CR845, which is in Phase I clinical trials to treat acute and chronic pain; and CR701 that is in preclinical trials for treating neuropathic and inflammatory pain. The company was founded in 2004 and is based in Shelton, Connecticut.
Home Page: www.caratherapeutics.com
CARA Technical Analysis
4 Stamford Plaza
Stamford,
CT
06902
United States
Phone:
203 406 3700
Officers
| Name | Title |
|---|---|
| Mr. Christopher A. Posner | Pres, CEO & Director |
| Dr. Derek T. Chalmers D.Sc., Ph.D. | Co-Founder & Sr. Advisor |
| Dr. Frédérique Menzaghi | Chief Scientific Officer and Sr. VP of R&D |
| Mr. Scott M. Terrillion | Chief Compliance Officer, Gen. Counsel & Corp. Sec. |
| Dr. Joana Goncalves | Chief Medical Officer |
| Mr. Ryan D. Maynard | Chief Financial Officer |
| Dr. Iris Francesconi Ph.D. | Chief Strategy Officer & Head of Investor Relations |
| Mr. Eric Vandal | Sr. VP of Commercial |
| Ms. Beth Weinberg | Sr. VP of Regulatory Affairs & QA |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.3987 |
| Price-to-Sales TTM: | 15.2232 |
| IPO Date: | 2014-01-31 |
| Fiscal Year End: | December |
| Full Time Employees: | 84 |